<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28570603</article-id><article-id pub-id-type="pmc">5453566</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0178669</article-id><article-id pub-id-type="publisher-id">PONE-D-17-07378</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Salmonella</subject><subj-group><subject>Salmonella Typhi</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Salmonella</subject><subj-group><subject>Salmonella Typhi</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Salmonella</subject><subj-group><subject>Salmonella Typhi</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Enterobacteriaceae</subject><subj-group><subject>Salmonella</subject><subj-group><subject>Salmonella Typhi</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>T Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-Linked Immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Spectrum Analysis Techniques</subject><subj-group><subject>Spectrophotometry</subject><subj-group><subject>Cytophotometry</subject><subj-group><subject>Flow Cytometry</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Evolution of <italic>Salmonella Typhi</italic> outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial</article-title><alt-title alt-title-type="running-head">Ty21a vaccination induces porin-specific immune responses</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Carre&#x000f1;o</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Perez-Shibayama</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gil-Cruz</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lopez-Macias</surname><given-names>Constantino</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vernazza</surname><given-names>Pietro</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7685-573X</contrib-id><name><surname>Ludewig</surname><given-names>Burkhard</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Albrich</surname><given-names>Werner C.</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Medical Research Unit on Immunochemistry (UIMIQ), Specialties Hospital, National Medical Centre &#x0201c;Siglo XXI&#x0201d;, Mexican Social Security Institute (IMSS), Mexico City, Mexico</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Borrow</surname><given-names>Ray</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Public Health England, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> BL PV WA.</p></list-item><list-item><p><bold>Data curation:</bold> JMC CPS CGC.</p></list-item><list-item><p><bold>Formal analysis:</bold> JMC CPS CGC.</p></list-item><list-item><p><bold>Funding acquisition:</bold> BL CLM JMC.</p></list-item><list-item><p><bold>Investigation:</bold> JMC CPS CGC.</p></list-item><list-item><p><bold>Methodology:</bold> BL PV WA CLM.</p></list-item><list-item><p><bold>Project administration:</bold> BL WA JMC CGC.</p></list-item><list-item><p><bold>Resources:</bold> WA PV CLM BL.</p></list-item><list-item><p><bold>Supervision:</bold> BL PV WA.</p></list-item><list-item><p><bold>Validation:</bold> BL PV.</p></list-item><list-item><p><bold>Visualization:</bold> JMC CPS CGC.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> JMC CPS CGC BL.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> BL CPS CGC.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>burkhard.ludewig@kssg.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>6</issue><elocation-id>e0178669</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Carre&#x000f1;o et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Carre&#x000f1;o et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0178669.pdf"/><abstract><p>Vaccination against complex pathogens such as typhoidal and non-typhoidal <italic>Salmonella</italic> requires the concerted action of different immune effector mechanisms. Outer membrane proteins (Omps) of <italic>Salmonella</italic> Typhi are potent immunogens, which elicit long-lasting and protective immunity. Here, we followed the evolution of <italic>S</italic>. Typhi OmpC and F-specific T and B cell responses in healthy volunteers after vaccination with the vaccine strain Ty21a. To follow humoral and cellular immune responses, pre- and post-vaccination samples (PBMC, serum and stool) collected from 15 vaccinated and 5 non-vaccinated individuals. Immunoglobulin levels were assessed in peripheral blood by enzyme-linked immunosorbent assay. B cell and T cell activation were analyzed by flow cytometry. We observed a significant increase of circulating antibody-secreting cells and maximal Omp-specific serum IgG titers at day 25 post vaccination, while IgA titers in stool peaked at day 60. Likewise, Omp-specific CD4<sup>+</sup> T cells in peripheral blood showed the highest expansion at day 60 post vaccination, concomitant with a significant increase in IFN-&#x003b3; and TNF&#x003b1; production. These results indicate that <italic>S</italic>. Typhi Omp-specific B cell responses and polyfunctional CD4<sup>+</sup> T cell responses evolve over a period of at least two months after application of the live attenuated vaccine. Moreover, these findings underscore the potential of <italic>S</italic>. Typhi Omps as subunit vaccine components.</p><p><bold>Trial registration:</bold>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/ISRCTN18360696">ISRCTN18360696</ext-link></p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100008391</institution-id><institution>UBS Optimus Foundation</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7685-573X</contrib-id><name><surname>Ludewig</surname><given-names>Burkhard</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100005688</institution-id><institution>Gottfried und Julia Bangerter-Rhyner-Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7685-573X</contrib-id><name><surname>Ludewig</surname><given-names>Burkhard</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Padella Foundation</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7685-573X</contrib-id><name><surname>Ludewig</surname><given-names>Burkhard</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004339</institution-id><institution>Stanley Thomas Johnson&#x000a0;Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7685-573X</contrib-id><name><surname>Ludewig</surname><given-names>Burkhard</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>Mexican National Council for Science and Technology</institution></funding-source><award-id>CB-2015-256402</award-id><principal-award-recipient><name><surname>Lopez-Macias</surname><given-names>Constantino</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100005343</institution-id><institution>Fundaci&#x000f3;n IMSS</institution></institution-wrap></funding-source><award-id>FIS/IMSS/PROT/MD15/1511</award-id><principal-award-recipient><name><surname>Lopez-Macias</surname><given-names>Constantino</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution>Fundaci&#x000f3;n IMSS</institution></funding-source><award-id>FIS/IMSS/PROT/MD16/1563</award-id><principal-award-recipient><name><surname>Lopez-Macias</surname><given-names>Constantino</given-names></name></principal-award-recipient></award-group><award-group id="award008"><funding-source><institution>Mexican National Council for Science and Technology</institution></funding-source><principal-award-recipient><name><surname>Carre&#x000f1;o</surname><given-names>Juan Manuel</given-names></name></principal-award-recipient></award-group><funding-statement>This study received financial support from the UBS Optimus Foundation, the Stanley Thomas Johnson Foundation, the Padella Foundation, the Bangeter-Rhyner Foundation (to BL), the Mexican National Council for Science and Technology (CONACyT) project number CB-2015-256402, and IMMS projects: FIS/IMSS/PROT/MD15/1511 and FIS/IMSS/PROT/MD16/1563 (to CLM). JMC received an international PhD fellowship from CONACyT. The funders had no role in study design, data collection or analysis, the decision to publish or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p><italic>Salmonella</italic> enterica serovar Typhi (<italic>S</italic>. Typhi) is an orally transmitted bacterial pathogen that infects only humans. Protective immune responses against this pathogen include the interaction of innate and adaptive immune mechanisms [<xref rid="pone.0178669.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0178669.ref002" ref-type="bibr">2</xref>]. Due to the host restriction, studies on disease pathogenesis and immune protection in the natural host are limited [<xref rid="pone.0178669.ref003" ref-type="bibr">3</xref>]. The Ty21a live attenuated vaccine strain represents a valuable model for studying immune responses that develop during infection with typhoidal <italic>Salmonella</italic> [<xref rid="pone.0178669.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0178669.ref004" ref-type="bibr">4</xref>]. Indeed, several studies have described the induction of humoral and cellular immune responses against different components of Ty21a after vaccination of healthy volunteers [<xref rid="pone.0178669.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0178669.ref011" ref-type="bibr">11</xref>]. For example, IgM, IgG and IgA antibodies against membrane proteins can be detected in the plasma of healthy individuals even before the vaccination. However, ex vivo cultures of lymphocytes obtained early after Ty21a vaccination revealed higher levels of specific antibodies in supernatants compared to controls indicating that systemic B cell responses are swiftly activated after encounter of Salmonella antigens [<xref rid="pone.0178669.ref006" ref-type="bibr">6</xref>]. Antibodies against the O-9,12 antigen, plasmablasts specific for lipopolysaccharide (LPS), and flagellin [<xref rid="pone.0178669.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0178669.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0178669.ref012" ref-type="bibr">12</xref>] can be detected in circulation as early as day 7 after vaccination. Examination of immune cell properties revealed that <italic>S</italic>. Typhi-specific T cells bear homing receptors for intestinal tissues [<xref rid="pone.0178669.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0178669.ref011" ref-type="bibr">11</xref>], while the induction effector memory CD8<sup>+</sup> T cells by Ty21a vaccination [<xref rid="pone.0178669.ref013" ref-type="bibr">13</xref>] suggests that cytotoxic T cell responses could at least in part contribute to the protection exerted by the vaccine. Furthermore, cross-reactive cellular immune responses include multifunctional CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref rid="pone.0178669.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0178669.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0178669.ref014" ref-type="bibr">14</xref>] underscoring the importance of multiple layers of immune mechanisms involved in the protection against this bacterial infection [<xref rid="pone.0178669.ref015" ref-type="bibr">15</xref>]. However, a broad range of immune responses directed against different target structures is not always advantageous for the host. For example, dysregulated B cell responses against LPS favor replication of non-typhoidal <italic>Salmonella</italic> in human immunodeficiency virus (HIV)-infected individuals leading to reduced bactericidal activity of antibodies against otherwise protective bacterial antigens [<xref rid="pone.0178669.ref016" ref-type="bibr">16</xref>]. Hence, it is important to analyze the development of immune responses directed against protective antigens such as flagellin [<xref rid="pone.0178669.ref017" ref-type="bibr">17</xref>] or outer membrane proteins (Omps) [<xref rid="pone.0178669.ref016" ref-type="bibr">16</xref>] in the context of complex antigenic exposure such as vaccination with a live attenuated pathogen.</p><p>Pore-forming Omps (also known as porins) represent important antigenic targets for an efficient response against <italic>Salmonella</italic>. The immune response against these proteins is shaped initially through the direct TLR-dependent stimulation of antigen presenting cells [<xref rid="pone.0178669.ref018" ref-type="bibr">18</xref>]. Subsequently, porin-specific CD4<sup>+</sup> T cells promote protective antibody responses via production of IFN- &#x003b3; and other cytokines [<xref rid="pone.0178669.ref019" ref-type="bibr">19</xref>]. Individuals recovering from typhoid fever possess circulating IgG and IgM antibodies against porins [<xref rid="pone.0178669.ref020" ref-type="bibr">20</xref>] and purified <italic>S</italic>. Typhi OmpC and F, which form the major Omp fractions of <italic>S</italic>. Typhi, and induce IgM and IgG bactericidal antibodies in mice and humans [<xref rid="pone.0178669.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0178669.ref021" ref-type="bibr">21</xref>]. A vaccine candidate based on purified <italic>S</italic>. Typhi OmpC and F has been tested in a clinical trial revealing safety and immunogenicity following subcutaneous application [<xref rid="pone.0178669.ref022" ref-type="bibr">22</xref>]. Currently, novel formulations of <italic>S</italic>. Typhi porins for oral application are under investigation using encapsulation into biocompatible copolymers of lactic and glycolic acid (PLGA) microparticles rendering the proteins resistant to gastric acids [<xref rid="pone.0178669.ref023" ref-type="bibr">23</xref>].</p><p>To follow the evolution of <italic>S</italic>. Typhi OmpC and F-specific T and B cell responses in the natural host, we vaccinated healthy volunteers with the live attenuated vaccine strain Ty21a [<xref rid="pone.0178669.ref024" ref-type="bibr">24</xref>]. We found a significant increase in antibody-secreting cells present in peripheral blood and maximal serum IgG titers at day 25 post vaccination. Interestingly, both IgA titers in stool and Omp-specific polyfunctional CD4<sup>+</sup> T cells in peripheral blood peaked at day 60 indicating that <italic>S</italic>. Typhi Omp-specific adaptive immune responses evolve over a period of at least two months after vaccination.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Subjects, vaccination and sample collection</title><p>This open, interventional study was approved by the Ethics Commission of the Canton St. Gallen (EKSG 15/085) and has been published as ISRCTN18360696 (DOI 10.1186/ISRCTN18360696). Before enrolment, subjects were informed about the purpose of the study and written informed consent was obtained in compliance with local and global regulations (<xref ref-type="supplementary-material" rid="pone.0178669.s002">S1 File</xref> and <xref ref-type="supplementary-material" rid="pone.0178669.s003">S2 File</xref>). A physical examination and a medical questionnaire to ensure the health status of the participants were performed. Healthy volunteers enrolled in the study were 18&#x02013;50 years old, without any previous vaccination against typhoid fever or infection with <italic>S</italic>. Typhi, with a negative test for HIV infection and a negative pregnancy test. In order to minimize bias block randomization was used. Randomization sequence was created with a 1:3 allocation using random block sizes of 4. Twenty volunteers were enrolled for the study from these, five volunteers were assigned as controls (all females, mean age 29.4 &#x000b1; 6.4 years old), and 15 volunteers were assigned to the vaccinated group (10 females and 5 males, mean age 35.9 &#x000b1; 8.4 years old) (<xref ref-type="table" rid="pone.0178669.t001">Table 1</xref>). One volunteer of the vaccinated group abandoned the study before completion (<xref ref-type="fig" rid="pone.0178669.g001">Fig 1</xref>). Three enteric-coated capsules each containing 2&#x02013;10&#x000d7;10<sup>9</sup> live and 5&#x02013;50&#x000d7;10<sup>9</sup> dead lyophilized Ty21a bacteria (Crucell) [<xref rid="pone.0178669.ref024" ref-type="bibr">24</xref>] were administered orally every other day with lukewarm water; the subjects of the control group received no treatment. Blood and stool samples were collected before vaccination (day 0) and on days 11, 25 and 60 after application of the first vaccine dose (<xref ref-type="table" rid="pone.0178669.t001">Table 1</xref>) and tested in a blinded fashion in regards to study group and tested in a blinded fashion in regards to study group assignment. PBMCs were isolated using Vacutainer CPT Ficoll tubes (Becton Dickinson) and frozen at -150&#x000b0;C in FCS with 10% DMSO (Sigma-Aldrich). Feces were mechanically disrupted, diluted (50% w/v) in a PBS solution containing 10% FCS and a protease inhibitor cocktail (1:500, Sigma-Aldrich) and centrifuged at 14,000 rpm at 4&#x000b0;C for 10 min. Clarified supernatants were collected and stored at -70&#x000b0;C until IgA measurement by ELISA. This study took place in the Kantonsspital St. Gallen, St. Gallen, Switzerland. The recruitment of the volunteers for the study started on June 15<sup>th</sup>, 2015, and ended on September 15<sup>th</sup>, 2015. The consort checklist of information to include when reporting a randomized trial is shown in <xref ref-type="supplementary-material" rid="pone.0178669.s004">S3 File</xref>.</p><fig id="pone.0178669.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178669.g001</object-id><label>Fig 1</label><caption><title>Study design.</title><p>CONSORT flow diagram indicating the number of participants that have been included and have completed the study.</p></caption><graphic xlink:href="pone.0178669.g001"/></fig><table-wrap id="pone.0178669.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178669.t001</object-id><label>Table 1</label><caption><title>Study demographic details.</title></caption><alternatives><graphic id="pone.0178669.t001g" xlink:href="pone.0178669.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">Gender (F/M)</th><th align="center" rowspan="1" colspan="1">Age (years)<xref ref-type="table-fn" rid="t001fn001"><sup>#</sup></xref></th><th align="center" rowspan="1" colspan="1">Vaccination</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Vaccinated</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">(10/5)</td><td align="center" rowspan="1" colspan="1">35.9 &#x000b1; 8.4</td><td align="center" rowspan="1" colspan="1">Vivotif</td></tr><tr><td align="center" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5/0</td><td align="center" rowspan="1" colspan="1">29.4 &#x000b1; 6.4</td><td align="center" rowspan="1" colspan="1">none</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p># Mean &#x000b1; standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec004"><title>Production of S. Typhi Omps</title><p>OmpC and F proteins were purified from <italic>S</italic>. Typhi ATCC 9993 as previously described [<xref rid="pone.0178669.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0178669.ref022" ref-type="bibr">22</xref>]. LPS content was determined using the limulus amebocyte lysate (LAL) assay (Charles River Endosafe Laboratories), and all batches were found to be negative with a detection limit 0.2 ng LPS/mg protein. Western blot analysis using anti-LPS polyclonal sera confirmed that LPS was not detectable by these means.</p></sec><sec id="sec005"><title>Detection of OmpC/F-specific antibodies</title><p>Antibody titers against S. Typhi OmpC/F in sera were determined as previously described [<xref rid="pone.0178669.ref022" ref-type="bibr">22</xref>]. Briefly, high-binding 96-well polystyrene plates (Corning) were coated with 10 &#x003bc;g/ml of the protein preparation in 0.1 M carbonate-bicarbonate buffer, pH 9.5. Plates were incubated for 1 h at 37&#x000b0;C and then overnight at 4&#x000b0;C. Before use, plates were washed three times with PBS containing 0.05% Tween-20 (PBS-T) (Sigma&#x02013;Aldrich). Non-specific binding was blocked with 5% non-fat dry milk diluted in PBS (PBS-M) for 1 h at 37&#x000b0;C. After washing, sera were diluted 1:40 and stool extracts 1:2, both in PBS-M and twofold serial dilutions were added to the wells. Plates were incubated for 1 h at 37&#x000b0;C, followed by four washes with PBS-T. After 1 h of incubation at 37&#x000b0;C with peroxidase-conjugated rabbit anti-human IgG (1:10,000) or IgM (1:5000) antibody (in PBS-M, Jackson Immuno Research), four washes with PBS-T, ortho-phenylenediamine (0.5 mg/ml; Sigma) in 0.1 M citrate buffer, pH 5.6, containing 0.08% H<sub>2</sub>O<sub>2</sub> was used to develop the reaction. Optical density was read at 492 nm using an automated ELISA plate reader (Tecan). Antibody titers are given as -log2 dilution &#x000d7; 40. Antibody titers were defined as the highest dilution of the sample at which the OD was higher than the mean &#x000b1; 3 SD of the negative sample values.</p></sec><sec id="sec006"><title>Identification of antibody secreting cells and activated B cells by flow cytometry</title><p>Activated B cells (ABC) and antibody secreting cells (ASC) were measured in blood as previously described [<xref rid="pone.0178669.ref025" ref-type="bibr">25</xref>]. Briefly, 10<sup>6</sup> PBMCs were stained using the following: PerCP anti-human CD14, PerCP anti-human CD16 and APC-Cy7 anti-human CD20 from Biolegend; PerCP anti-human CD3, PE anti-human IgD, APC anti-human CD38, FITC anti-human CD19, and PECy7 anti-human CD71 from eBiosciences; the fixable viability stain 510 (e-Biosciences) was used to discriminate dead cells. Samples were stained for 30 min on ice with the viability dye, washed and stain for 20 min at 4&#x000b0;C with the required antibodies. Flow cytometric analysis was performed using a LSR-FORTESSA (Becton Dickinson). Data were analyzed using FlowJo software 10 (Tree Star, USA).</p></sec><sec id="sec007"><title>In vitro stimulation and assessment CD4<sup>+</sup> T cell responses</title><p>CD4<sup>+</sup> T cell activation profile was assessed as previously described [<xref rid="pone.0178669.ref026" ref-type="bibr">26</xref>]. Briefly, 10<sup>6</sup> PBMCs in RPMI 1640 medium containing 5% FCS, 1% penicillin-streptomycin were stimulated with 10 &#x003bc;g/ml of <italic>S</italic>. Typhi OmpC/F or 50 &#x003bc;g/ml of tetanus toxoid for 24h at 37&#x000b0;C. After <italic>in vitro</italic> stimulation, surface staining was performed and the frequency of CD4<sup>+</sup> T cells and intracellular expression of CD40L, IFN- &#x003b3; and TNF was assessed by flow cytometry using the following antibodies: PerCP/Cy5.5 anti-human CD3, PE/Cy7 anti-human CD4 and FITC anti-human CD154, PE anti-human IFN- &#x003b3; and APC anti-human TNF (all from Biolegend); the fixable viability stain 780 (e-Biosciences) was used to discriminate dead cells. Samples were analyzed using a FACS Canto flow cytometer (Becton Dickinson), and data were analyzed using FlowJo software version 10 (Tree Star, USA).</p></sec><sec id="sec008"><title>Statistical analysis</title><p>Statistical analyses were performed with Graphpad Prism 5.0 (GraphPad Software Inc. USA) using two tailed Student&#x02019;s <italic>t</italic> test with Welch&#x02019;s correction. Statistical analysis was performed using one way ANOVA with Dunnett&#x02019;s multiple comparison test for comparisons between individuals of the same group at different time points (pre- versus post-vaccination) Statistical significance was defined as p &#x0003c; 0.05. Raw data is available as <xref ref-type="supplementary-material" rid="pone.0178669.s005">S4 File</xref>.</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>Vaccine-induced B cell activation pattern in peripheral blood</title><p>After infection or vaccination, pathogen-specific B cells proliferate and differentiate into antibody-secreting cells (ASCs) or memory B cells [<xref rid="pone.0178669.ref027" ref-type="bibr">27</xref>]. Following re-encounter with the pathogen, swift production of protective antibodies is secured by long-lived ASCs and rapid differentiation of memory B cells into ASCs [<xref rid="pone.0178669.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0178669.ref029" ref-type="bibr">29</xref>]. In order to assess how oral exposure to attenuated <italic>S</italic>. Typhi Ty21a affects B cell activation, we performed a flow cytometric analysis of PBMCs. Surface markers CD20 and CD71 on switched IgD<sup>&#x02212;</sup>B cells were used to define either ASCs (CD20<sup>&#x02013;</sup> CD71<sup>+</sup>) or activated B cells (ABC, CD20<sup>hi</sup> CD71<sup>+</sup>) (<xref ref-type="fig" rid="pone.0178669.g002">Fig 2A</xref>). This analysis revealed that the volunteers responded to the vaccination with a significant increase in circulating ASCs at days 25 and 60 after oral administration of Ty21a, a finding that was corroborated using staining for the ASC marker CD38 (<xref ref-type="supplementary-material" rid="pone.0178669.s001">S1A and S1B Fig</xref>). Notably, peripheral ASCs in non-vaccinated individuals were not significantly changed (<xref ref-type="fig" rid="pone.0178669.g002">Fig 2B and 2C</xref> and <xref ref-type="supplementary-material" rid="pone.0178669.s001">S1C Fig</xref>), while both groups of volunteers did not show substantial differences in ABC numbers throughout the course of the observation period (<xref ref-type="fig" rid="pone.0178669.g002">Fig 2D</xref>). These results indicate that oral exposure to <italic>S</italic>. Typhi Ty21a induces B cell activation and differentiation towards ASCs, which can be traced in peripheral blood of vaccinated individuals.</p><fig id="pone.0178669.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178669.g002</object-id><label>Fig 2</label><caption><title>Identification of activated B cells and antibody secreting cells in peripheral blood following Ty21a vaccination.</title><p>PBMCs were collected from vaccinated or control (Ctrl) subjects at the indicated time points and analysis of different B cell populations was performed by flow cytometry. (A) Gating strategy for FACS analysis of activated B cells (ABC, blue) or antibody secreting cells (ASC, red). (B) Representative dot plots showing the proportions of ABC (CD20<sup>hi</sup> CD71<sup>+</sup>) and ASC (CD20<sup>-</sup> CD71<sup>+</sup>) in vaccinated and Ctrl individuals at the indicated time points. (C and D). Proportions of ABC and ASC in vaccinated and Ctrl individuals at the indicated time points. Dots represent individual values; bars indicate mean &#x000b1; SEM. Statistical analysis was performed using one way ANOVA with Dunnett&#x02019;s multiple comparison test for comparisons between individuals of the same group at different time points (pre- versus post-vaccination) (*, P&#x0003c; 0.05; **, P&#x0003c; 0.01).</p></caption><graphic xlink:href="pone.0178669.g002"/></fig></sec><sec id="sec011"><title>Induction of OmpC/F-specific antibodies</title><p>Humoral responses against membrane proteins and O-9,12 antigen can be detected as early as 7 days after vaccination with Ty21a [<xref rid="pone.0178669.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0178669.ref009" ref-type="bibr">9</xref>], which is consistent with our finding that vaccinated individuals exhibited an increase of ASC in peripheral blood at day 11 post vaccination (<xref ref-type="fig" rid="pone.0178669.g002">Fig 2C</xref>). To assess whether the elevated B cell response was directed against <italic>S</italic>. Typhi porins OmpC and F, we determined anti-OmpC/F IgG and IgM antibody titers before and after vaccination. We found that all individuals showed IgM seroreactivity against OmpC and F and that exposure to the live attenuated vaccine did not drastically change the anti-OmpC/F IgM response (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3A</xref>). In contrast, only 5 out of 14 individuals showed pre-existing anti-OmpC/F IgG antibodies and all but 2 individuals responded with an increase of specific IgG titers at one or more time points post vaccination (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3B</xref>). Despite the high inter-individual variation, the pre- versus post-vaccination antibody titers were statistically significant at all time points for both anti-OmpC/F IgM (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3C</xref>) and IgG (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3D</xref>). OmpC/F-specific IgM antibody titers peaked at day 11 post vaccination (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3C</xref>), while IgG values were highest at day 25 (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3D</xref>). Likewise, mean anti-OmpC/F IgA antibodies in stool reached highest levels at day 25 and remained significantly elevated until day 60 post vaccination (<xref ref-type="fig" rid="pone.0178669.g003">Fig 3E</xref>). These data indicate that optimal antibody responses against <italic>S</italic>. Typhi OmpC and F develop over a period of two months.</p><fig id="pone.0178669.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178669.g003</object-id><label>Fig 3</label><caption><title>Induction of anti-OmpC/F-specific porin antibodies in serum and stool after Ty21a vaccination.</title><p>(A) IgM and (B) IgG, OmpC/F-specific antibody titers in serum samples from vaccinated subjects were analyzed by ELISA at the indicated time points after vaccination; participant numbers assigned according to increasing IgG reactivity. (C and D) Kinetics of anti-OmpC/F IgM (C) and IgG (D) antibody titers in vaccinated or control (Ctrl) individuals. Dots represent individual values; bars indicate mean &#x000b1; SEM. (E) <italic>S</italic>. Typhi OmpC/F-specific IgA was determined from stool samples from vaccinated or Ctrl subjects by ELISA. Dots represent individual values; bars represent mean &#x000b1; SEM. Statistical analysis was performed using one way ANOVA with Dunnett&#x02019;s multiple comparison test for comparisons between individuals of the same group at different time points (pre- versus post-vaccination) (*, P&#x0003c; 0.05; **, P&#x0003c; 0.01 ***, P&#x0003c;0.001).</p></caption><graphic xlink:href="pone.0178669.g003"/></fig></sec><sec id="sec012"><title>Polyfunctional CD4<sup>+</sup> T cell responses after Ty21a vaccination</title><p>Immunity against <italic>S</italic>. Typhi requires the concerted action of both B cell and T cells responses whereby provision of IFN- &#x003b3; and other cytokines by CD4<sup>+</sup> T cells is key for the control of the bacterial infection [<xref rid="pone.0178669.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0178669.ref015" ref-type="bibr">15</xref>]. To characterize the <italic>S</italic>. Typhi-induced T cell response in humans in more detail, we analyzed the activation profile of CD4<sup>+</sup> T cells from PBMCs using <italic>in vitro</italic> stimulation with <italic>S</italic>. Typhi OmpC/F porins or tetanus toxoid (TT) as a control antigen. As shown in <xref ref-type="fig" rid="pone.0178669.g003">Fig 3A and 3B</xref>, intracellular CD40L expression served as activation marker to distinguish antigen-specific CD4<sup>+</sup> T cells [<xref rid="pone.0178669.ref026" ref-type="bibr">26</xref>] (<xref ref-type="fig" rid="pone.0178669.g004">Fig 4A and 4B</xref>). While TT-specific CD4<sup>+</sup> T cell activation was not altered during the course for Ty21a vaccination (<xref ref-type="fig" rid="pone.0178669.g004">Fig 4C</xref>), the fraction of OmpC/F-specific CD4<sup>+</sup> T cells in peripheral blood had significantly increased by day 25 and was further augmented until day 60 (<xref ref-type="fig" rid="pone.0178669.g004">Fig 4D</xref>). Moreover, a substantial fraction of CD40L-expressing CD4<sup>+</sup> T cells produced both IFN- &#x003b3; and TNF following exposure to the antigen (<xref ref-type="fig" rid="pone.0178669.g004">Fig 4E</xref>). We observed a significant increase of such polyfunctional CD4<sup>+</sup> T cells from day 11 to day 60 post vaccination in peripheral blood (<xref ref-type="fig" rid="pone.0178669.g004">Fig 4F</xref>) indicating that the live attenuated Ty21a exerts a persisting differentiation stimulus for OmpC/F-specific T cells. Evaluation of OmpC/F-specific revealed only very limited TNF-&#x003b1; and IFN- &#x003b3; production by CD8<sup>+</sup> T cells from 6 out of the 14 vaccinated volunteers (data not shown) suggesting that exposure to OmpC/F in the context of oral Ty21a immunization elicits mainly long lasting CD4<sup>+</sup> T cell and antibody responses.</p><fig id="pone.0178669.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0178669.g004</object-id><label>Fig 4</label><caption><title>Activation profile of OmpC/F-specific CD4<sup>+</sup> T cells after Ty21a vaccination.</title><p>PBMCs were collected from vaccinated or control (Ctrl) subjects at the indicated time points. Activation of CD4<sup>+</sup> T cells was assessed by flow cytometry after 24 h incubation with the indicated antigen. (A) Gating strategy for FACS analysis. (B) Representative dot plots showing the proportions of CD4<sup>+</sup> CD40L<sup>+</sup> T cells of Ctrl (upper panels) or vaccinated (lower panels) subjects after stimulation with <italic>S</italic>. Typhi OmpC/F porins or tetanus toxoid (TT). (C and D) Proportions of CD4<sup>+</sup> CD40L<sup>+</sup> T cells stimulated with TT (C) or OmpC/F (D) at the indicated time points. Dots represent individual values; bars represent mean &#x000b1; SEM. (E) Representative dot plot showing IFN- &#x003b3; and TNF-&#x003b1; production out of CD4<sup>+</sup> CD40L<sup>+</sup> cells after stimulation using medium or OmpC/F porins. (F) Proportions of OmpC/F-specific polyfunctional cells (IFN- &#x003b3; <sup>+</sup> and/or TNF- &#x003b1;<sup>+</sup>) out of CD4<sup>+</sup> CD40L<sup>+</sup> T cells at indicated time points after vaccination in responder individuals. Statistical analysis in panels C and D was performed using one way ANOVA with Dunnett&#x02019;s multiple comparison test for comparisons between individuals of the same group at different time points (pre- versus post-vaccination) or unpaired Student&#x02019;s <italic>t</italic> test with Welch&#x02019;s correction for comparison between Ctrl and vaccinated groups. Statistical analysis in panel F was performed using paired Student&#x02019;s <italic>t</italic> test for comparison between individuals of the same group (Day 11 versus Day 60) (*, P&#x0003c; 0.05; **, P&#x0003c; 0.01).</p></caption><graphic xlink:href="pone.0178669.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>A better understanding of immunological processes occurring during <italic>S</italic>. Typhi infection and the re-definition of potential targets with protective properties are required to improve efficacy of the current typhoid vaccines. In this study, we have analyzed the evolution of B and T cell responses elicited by the <italic>S</italic>. Typhi porins OmpC and F during the course of infection with the live attenuated <italic>S</italic>. Typhi strain Ty21a. Previous studies have evaluated immune responses against <italic>S</italic>. Typhi antigens such the LPS [<xref rid="pone.0178669.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0178669.ref009" ref-type="bibr">9</xref>], the flagellar H-antigen [<xref rid="pone.0178669.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0178669.ref012" ref-type="bibr">12</xref>], or the oligosaccharide O-antigen [<xref rid="pone.0178669.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0178669.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0178669.ref030" ref-type="bibr">30</xref>]. We found that vaccination Ty21a elicited a substantial increase in ASC in the peripheral blood and that OmpC/F-specific antibodies significantly increased indicating that a strong polyclonal B cell response had been elicited against these antigens. Since patients in convalescence stages of typhoid fever show circulating IgM and IgG directed against OmpC and F [<xref rid="pone.0178669.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0178669.ref031" ref-type="bibr">31</xref>], it is most likely that <italic>S</italic>. Typhi porins contribute to protection against typhoid fever. Hence, our study confirms that porins represent highly immunogenic targets that can elicit significant IgA, IgM and IgG which have been shown to confer protection against <italic>Salmonella</italic> infection [<xref rid="pone.0178669.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0178669.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0178669.ref032" ref-type="bibr">32</xref>].</p><p><italic>S</italic>. Typhi is an intracellular pathogen that can only be controlled if efficient T cell responses are induced [<xref rid="pone.0178669.ref001" ref-type="bibr">1</xref>]. While several studies have shown that <italic>S</italic>. Typhi infection or vaccination with Ty21a induce CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses against several antigens, the magnitude and kinetics of CD4<sup>+</sup> T cell responses against OmpC and F porins following Ty21a administration had not been assessed. Our study shows that the majority of the volunteers generated specific CD4<sup>+</sup> T cell responses against OmpC and F porins following Ty21a administration indicating that these antigens contribute to the global CD4<sup>+</sup> T cell response elicited by <italic>S</italic>. Typhi. Moreover, we found that volunteers vaccinated with Ty21a generated OmpC and F specific CD4<sup>+</sup> T cells with a multifunctional cytokine production profile. These findings are in line with the finding that Ty21a vaccination elicits multifunctional CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses against multiple antigens [<xref rid="pone.0178669.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0178669.ref014" ref-type="bibr">14</xref>]. Our results suggest that a substantial fraction of multifunctional CD4<sup>+</sup> T cells recognize OmpC and F porins following vaccination with Ty21a and&#x02013;most likely&#x02013;during <italic>S</italic>. Typhi infection. Since porins are highly conserved proteins in <italic>Salmonella</italic> species [<xref rid="pone.0178669.ref033" ref-type="bibr">33</xref>], it is possible that vaccination with <italic>S</italic>. Typhi porins could elicit cross-protection against other <italic>Salmonella</italic> serovars. Indeed, cross-reactive T cell responses have been described in volunteers vaccinated with Ty21a [<xref rid="pone.0178669.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0178669.ref014" ref-type="bibr">14</xref>]. Moreover, exposure to Ty21a induces a strong IgA response against Omps from <italic>S</italic>. Typhi and <italic>S</italic>. Paratyphi B, but not against Omps from <italic>S</italic>. Paratyphi A [<xref rid="pone.0178669.ref034" ref-type="bibr">34</xref>]. Hence, further studies of cellular and humoral immune responses directed against well-characterized <italic>Salmonella</italic> antigens are warranted to further optimize the current vaccines and to develop approaches that facilitate the induction of effective immune responses that are directed against protective antigens.</p></sec><sec sec-type="supplementary-material" id="sec014"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0178669.s001"><label>S1 Fig</label><caption><title>Identification of CD38+ antibody secreting cells in peripheral blood following Ty21a vaccination.</title><p>PBMCs were collected from vaccinated or control (Ctrl) subjects at the indicated time points and analysis of different B cell populations was performed by flow cytometry. (A) Gating strategy for FACS analysis of IgD<sup>-</sup> CD38<sup>-</sup> B cells (blue) or CD38<sup>+</sup> antibody secreting cells (ASC, red); representative dots plots on the right show the proportions of ASC (CD38<sup>+</sup> CD71<sup>+</sup>) in a vaccinated individual at the indicated time points. Proportions ASC in vaccinated (B) and Ctrl (C) individuals at the indicated time points. Dots represent individual values; bars indicate mean &#x000b1; SEM. Statistical analysis was performed using one way ANOVA with Dunnett&#x02019;s multiple comparison test for comparisons between individuals of the same group at different time points (pre- versus post-vaccination) (*, P&#x0003c; 0.05).</p><p>(PDF)</p></caption><media xlink:href="pone.0178669.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178669.s002"><label>S1 File</label><caption><title>Patient information in English.</title><p>(DOCX)</p></caption><media xlink:href="pone.0178669.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178669.s003"><label>S2 File</label><caption><title>Patient information in German.</title><p>(DOCX)</p></caption><media xlink:href="pone.0178669.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178669.s004"><label>S3 File</label><caption><title>Consort checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0178669.s004.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178669.s005"><label>S4 File</label><caption><title>Data tables.</title><p>(XLSX)</p></caption><media xlink:href="pone.0178669.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0178669.s006"><label>S1 Protocol</label><caption><p>(PDF)</p></caption><media xlink:href="pone.0178669.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors wish to acknowledge Dr. Ahmed N. Hegazy from the University of Oxford for his support in the assessment of the CD4<sup>+</sup> T cell activation profile from PBMC samples. We acknowledge the support of the Clinical Trials Unit and thank Cornelia Knapp and Simone Kessler for coordination of the clinical study, and Dr. Ana Steffen, Dr. Kerstin Wissel, Brigitta Rusch, Carina Bischof, Susanne St&#x000f6;lzl and Natalie Engeler for their clinical support. We greatly appreciate all volunteers for their participation in this study. This study received financial support from the UBS Optimus Foundation, the Stanley Thomas Johnson Foundation, the Padella Foundation, the Bangeter-Rhyner Foundation (to BL), the Mexican National Council for Science and Technology (CONACyT) project number CB-2015-256402, and IMMS projects: FIS/IMSS/PROT/MD15/1511 and FIS/IMSS/PROT/MD16/1563 (to CLM). JMC received an international PhD fellowship from CONACyT. The funders had no role in study design, data collection or analysis, the decision to publish or preparation of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0178669.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Gilchrist</surname><given-names>JJ</given-names></name>, <name><surname>MacLennan</surname><given-names>CA</given-names></name>, <name><surname>Hill</surname><given-names>AV</given-names></name>. <article-title>Genetic susceptibility to invasive Salmonella disease</article-title>. <source>Nat Rev Immunol</source>. <year>2015</year>;<volume>15</volume>(<issue>7</issue>):<fpage>452</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri3858">10.1038/nri3858</ext-link></comment>
<pub-id pub-id-type="pmid">26109132</pub-id></mixed-citation></ref><ref id="pone.0178669.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Wain</surname><given-names>J</given-names></name>, <name><surname>Hendriksen</surname><given-names>RS</given-names></name>, <name><surname>Mikoleit</surname><given-names>ML</given-names></name>, <name><surname>Keddy</surname><given-names>KH</given-names></name>, <name><surname>Ochiai</surname><given-names>RL</given-names></name>. <article-title>Typhoid fever</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>(<issue>9973</issue>):<fpage>1136</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(13)62708-7">10.1016/S0140-6736(13)62708-7</ext-link></comment>
<pub-id pub-id-type="pmid">25458731</pub-id></mixed-citation></ref><ref id="pone.0178669.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>de Jong</surname><given-names>HK</given-names></name>, <name><surname>Parry</surname><given-names>CM</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name>, <name><surname>Wiersinga</surname><given-names>WJ</given-names></name>. <article-title>Host-pathogen interaction in invasive Salmonellosis</article-title>. <source>PLoS Pathog</source>. <year>2012</year>;<volume>8</volume>(<issue>10</issue>):<fpage>e1002933</fpage> PubMed Central PMCID: PMCPMC3464234. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1002933">10.1371/journal.ppat.1002933</ext-link></comment>
<pub-id pub-id-type="pmid">23055923</pub-id></mixed-citation></ref><ref id="pone.0178669.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Kantele</surname><given-names>A</given-names></name>, <name><surname>Pakkanen</surname><given-names>SH</given-names></name>, <name><surname>Siitonen</surname><given-names>A</given-names></name>, <name><surname>Karttunen</surname><given-names>R</given-names></name>, <name><surname>Kantele</surname><given-names>JM</given-names></name>. <article-title>Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?</article-title>
<source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>50</issue>):<fpage>7238</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2012.10.002">10.1016/j.vaccine.2012.10.002</ext-link></comment>
<pub-id pub-id-type="pmid">23084770</pub-id></mixed-citation></ref><ref id="pone.0178669.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Cancellieri</surname><given-names>V</given-names></name>, <name><surname>Fara</surname><given-names>GM</given-names></name>. <article-title>Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine</article-title>. <source>J Infect Dis</source>. <year>1985</year>;<volume>151</volume>(<issue>3</issue>):<fpage>482</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="pmid">3882850</pub-id></mixed-citation></ref><ref id="pone.0178669.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Lundgren</surname><given-names>A</given-names></name>, <name><surname>Kaim</surname><given-names>J</given-names></name>, <name><surname>Jertborn</surname><given-names>M</given-names></name>. <article-title>Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods</article-title>. <source>Vaccine</source>. <year>2009</year>;<volume>27</volume>(<issue>33</issue>):<fpage>4529</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2009.05.005">10.1016/j.vaccine.2009.05.005</ext-link></comment>
<pub-id pub-id-type="pmid">19446596</pub-id></mixed-citation></ref><ref id="pone.0178669.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Pakkanen</surname><given-names>SH</given-names></name>, <name><surname>Kantele</surname><given-names>JM</given-names></name>, <name><surname>Kantele</surname><given-names>A</given-names></name>. <article-title>Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination</article-title>. <source>Vaccine</source>. <year>2012</year>;<volume>30</volume>(<issue>42</issue>):<fpage>6047</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2012.07.051">10.1016/j.vaccine.2012.07.051</ext-link></comment>
<pub-id pub-id-type="pmid">22858557</pub-id></mixed-citation></ref><ref id="pone.0178669.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Pennington</surname><given-names>SH</given-names></name>, <name><surname>Thompson</surname><given-names>AL</given-names></name>, <name><surname>Wright</surname><given-names>AK</given-names></name>, <name><surname>Ferreira</surname><given-names>DM</given-names></name>, <name><surname>Jambo</surname><given-names>KC</given-names></name>, <name><surname>Wright</surname><given-names>AD</given-names></name>, <etal>et al</etal>
<article-title>Oral Typhoid Vaccination With Live-Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a-Responsive and Heterologous Influenza Virus-Responsive CD4+ and CD8+ T Cells at the Human Intestinal Mucosa</article-title>. <source>J Infect Dis</source>. <year>2016</year>;<volume>213</volume>(<issue>11</issue>):<fpage>1809</fpage>&#x02013;<lpage>19</lpage>. PubMed Central PMCID: PMCPMC4857474. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiw030">10.1093/infdis/jiw030</ext-link></comment>
<pub-id pub-id-type="pmid">26810369</pub-id></mixed-citation></ref><ref id="pone.0178669.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Viret</surname><given-names>JF</given-names></name>, <name><surname>Favre</surname><given-names>D</given-names></name>, <name><surname>Wegmuller</surname><given-names>B</given-names></name>, <name><surname>Herzog</surname><given-names>C</given-names></name>, <name><surname>Que</surname><given-names>JU</given-names></name>, <name><surname>Cryz</surname><given-names>SJ</given-names><suffix>Jr.</suffix></name>, <etal>et al</etal>
<article-title>Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria</article-title>. <source>Infect Immun</source>. <year>1999</year>;<volume>67</volume>(<issue>7</issue>):<fpage>3680</fpage>&#x02013;<lpage>5</lpage>. PubMed Central PMCID: PMCPMC116565. <pub-id pub-id-type="pmid">10377160</pub-id></mixed-citation></ref><ref id="pone.0178669.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Fresnay</surname><given-names>S</given-names></name>, <name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a</article-title>. <source>Clin Immunol</source>. <year>2016</year>;<volume>173</volume>:<fpage>87</fpage>&#x02013;<lpage>95</lpage>. PubMed Central PMCID: PMCPMC5322816. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clim.2016.09.006">10.1016/j.clim.2016.09.006</ext-link></comment>
<pub-id pub-id-type="pmid">27634430</pub-id></mixed-citation></ref><ref id="pone.0178669.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Zafar</surname><given-names>SJ</given-names></name>, <name><surname>McArthur</surname><given-names>MA</given-names></name>, <name><surname>Pasetti</surname><given-names>MF</given-names></name>, <name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B</article-title>. <source>Clin Vaccine Immunol</source>. <year>2014</year>;<volume>21</volume>(<issue>3</issue>):<fpage>427</fpage>&#x02013;<lpage>34</lpage>. PubMed Central PMCID: PMCPMC3957674. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00786-13">10.1128/CVI.00786-13</ext-link></comment>
<pub-id pub-id-type="pmid">24429069</pub-id></mixed-citation></ref><ref id="pone.0178669.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Kantele</surname><given-names>A</given-names></name>. <article-title>Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine</article-title>. <source>Vaccine</source>. <year>1990</year>;<volume>8</volume>(<issue>4</issue>):<fpage>321</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">2396471</pub-id></mixed-citation></ref><ref id="pone.0178669.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Salerno-Goncalves</surname><given-names>R</given-names></name>, <name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Ex Vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine</article-title>. <source>Clin Vaccine Immunol</source>. <year>2010</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1305</fpage>&#x02013;<lpage>14</lpage>. PubMed Central PMCID: PMCPMC2944457. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00234-10">10.1128/CVI.00234-10</ext-link></comment>
<pub-id pub-id-type="pmid">20660136</pub-id></mixed-citation></ref><ref id="pone.0178669.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Fresnay</surname><given-names>S</given-names></name>, <name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans</article-title>. <source>Mucosal Immunol</source>. <year>2015</year>;<volume>8</volume>(<issue>6</issue>):<fpage>1349</fpage>&#x02013;<lpage>59</lpage>. PubMed Central PMCID: PMCPMC4607552. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/mi.2015.24">10.1038/mi.2015.24</ext-link></comment>
<pub-id pub-id-type="pmid">25872480</pub-id></mixed-citation></ref><ref id="pone.0178669.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Perez-Shibayama</surname><given-names>C</given-names></name>, <name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Ludewig</surname><given-names>B</given-names></name>. <article-title>Plasticity and complexity of B cell responses against persisting pathogens</article-title>. <source>Immunol Lett</source>. <year>2014</year>;<volume>162</volume>(<volume>1</volume> Pt A):<fpage>53</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.imlet.2014.07.003">10.1016/j.imlet.2014.07.003</ext-link></comment>
<pub-id pub-id-type="pmid">25068435</pub-id></mixed-citation></ref><ref id="pone.0178669.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>MacLennan</surname><given-names>CA</given-names></name>, <name><surname>Gilchrist</surname><given-names>JJ</given-names></name>, <name><surname>Gordon</surname><given-names>MA</given-names></name>, <name><surname>Cunningham</surname><given-names>AF</given-names></name>, <name><surname>Cobbold</surname><given-names>M</given-names></name>, <name><surname>Goodall</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults</article-title>. <source>Science</source>. <year>2010</year>;<volume>328</volume>(<issue>5977</issue>):<fpage>508</fpage>&#x02013;<lpage>12</lpage>. PubMed Central PMCID: PMCPMC3772309. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1180346">10.1126/science.1180346</ext-link></comment>
<pub-id pub-id-type="pmid">20413503</pub-id></mixed-citation></ref><ref id="pone.0178669.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Salerno-Goncalves</surname><given-names>R</given-names></name>, <name><surname>Tacket</surname><given-names>CO</given-names></name>, <name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>8</issue>):<fpage>1416</fpage>&#x02013;<lpage>25</lpage>. PubMed Central PMCID: PMCPMC1840048. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2006.10.040">10.1016/j.vaccine.2006.10.040</ext-link></comment>
<pub-id pub-id-type="pmid">17182155</pub-id></mixed-citation></ref><ref id="pone.0178669.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name>, <name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Pastelin-Palacios</surname><given-names>R</given-names></name>, <name><surname>Lang</surname><given-names>KS</given-names></name>, <name><surname>Isibasi</surname><given-names>A</given-names></name>, <name><surname>Ludewig</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens</article-title>. <source>Eur J Immunol</source>. <year>2009</year>;<volume>39</volume>(<issue>1</issue>):<fpage>126</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.200838185">10.1002/eji.200838185</ext-link></comment>
<pub-id pub-id-type="pmid">19130558</pub-id></mixed-citation></ref><ref id="pone.0178669.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Perez-Shibayama</surname><given-names>C</given-names></name>, <name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Pastelin-Palacios</surname><given-names>R</given-names></name>, <name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name>, <name><surname>Hisaki</surname><given-names>E</given-names></name>, <name><surname>Chai</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>IFN-gamma-producing CD4+ T cells promote generation of protective germinal center-derived IgM+ B cell memory against Salmonella Typhi</article-title>. <source>J Immunol</source>. <year>2014</year>;<volume>192</volume>(<issue>11</issue>):<fpage>5192</fpage>&#x02013;<lpage>200</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1302526">10.4049/jimmunol.1302526</ext-link></comment>
<pub-id pub-id-type="pmid">24778443</pub-id></mixed-citation></ref><ref id="pone.0178669.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Ortiz</surname><given-names>V</given-names></name>, <name><surname>Isibasi</surname><given-names>A</given-names></name>, <name><surname>Garcia-Ortigoza</surname><given-names>E</given-names></name>, <name><surname>Kumate</surname><given-names>J</given-names></name>. <article-title>Immunoblot detection of class-specific humoral immune response to outer membrane proteins isolated from Salmonella typhi in humans with typhoid fever</article-title>. <source>J Clin Microbiol</source>. <year>1989</year>;<volume>27</volume>(<issue>7</issue>):<fpage>1640</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">2768450</pub-id></mixed-citation></ref><ref id="pone.0178669.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Secundino</surname><given-names>I</given-names></name>, <name><surname>Lopez-Macias</surname><given-names>C</given-names></name>, <name><surname>Cervantes-Barragan</surname><given-names>L</given-names></name>, <name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Rios-Sarabia</surname><given-names>N</given-names></name>, <name><surname>Pastelin-Palacios</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response</article-title>. <source>Immunology</source>. <year>2006</year>;<volume>117</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-2567.2005.02263.x">10.1111/j.1365-2567.2005.02263.x</ext-link></comment>
<pub-id pub-id-type="pmid">16423041</pub-id></mixed-citation></ref><ref id="pone.0178669.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Salazar-Gonzalez</surname><given-names>RM</given-names></name>, <name><surname>Maldonado-Bernal</surname><given-names>C</given-names></name>, <name><surname>Ramirez-Cruz</surname><given-names>NE</given-names></name>, <name><surname>Rios-Sarabia</surname><given-names>N</given-names></name>, <name><surname>Beltran-Nava</surname><given-names>J</given-names></name>, <name><surname>Castanon-Gonzalez</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Induction of cellular immune response and anti-Salmonella enterica serovar typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever</article-title>. <source>Immunol Lett</source>. <year>2004</year>;<volume>93</volume>(<issue>2&#x02013;3</issue>):<fpage>115</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.imlet.2004.01.010">10.1016/j.imlet.2004.01.010</ext-link></comment>
<pub-id pub-id-type="pmid">15158606</pub-id></mixed-citation></ref><ref id="pone.0178669.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Carreno</surname><given-names>JM</given-names></name>, <name><surname>Perez-Shibayama</surname><given-names>C</given-names></name>, <name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Printz</surname><given-names>A</given-names></name>, <name><surname>Pastelin</surname><given-names>R</given-names></name>, <name><surname>Isibasi</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>(<issue>35</issue>):<fpage>4263</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2016.05.036">10.1016/j.vaccine.2016.05.036</ext-link></comment>
<pub-id pub-id-type="pmid">27372155</pub-id></mixed-citation></ref><ref id="pone.0178669.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Germanier</surname><given-names>R</given-names></name>, <name><surname>Fuer</surname><given-names>E</given-names></name>. <article-title>Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine</article-title>. <source>J Infect Dis</source>. <year>1975</year>;<volume>131</volume>(<issue>5</issue>):<fpage>553</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">1092768</pub-id></mixed-citation></ref><ref id="pone.0178669.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Ellebedy</surname><given-names>AH</given-names></name>, <name><surname>Jackson</surname><given-names>KJ</given-names></name>, <name><surname>Kissick</surname><given-names>HT</given-names></name>, <name><surname>Nakaya</surname><given-names>HI</given-names></name>, <name><surname>Davis</surname><given-names>CW</given-names></name>, <name><surname>Roskin</surname><given-names>KM</given-names></name>, <etal>et al</etal>
<article-title>Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination</article-title>. <source>Nat Immunol</source>. <year>2016</year>;<volume>17</volume>(<issue>10</issue>):<fpage>1226</fpage>&#x02013;<lpage>34</lpage>. PubMed Central PMCID: PMCPMC5054979. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.3533">10.1038/ni.3533</ext-link></comment>
<pub-id pub-id-type="pmid">27525369</pub-id></mixed-citation></ref><ref id="pone.0178669.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Frentsch</surname><given-names>M</given-names></name>, <name><surname>Arbach</surname><given-names>O</given-names></name>, <name><surname>Kirchhoff</surname><given-names>D</given-names></name>, <name><surname>Moewes</surname><given-names>B</given-names></name>, <name><surname>Worm</surname><given-names>M</given-names></name>, <name><surname>Rothe</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Direct access to CD4+ T cells specific for defined antigens according to CD154 expression</article-title>. <source>Nat Med</source>. <year>2005</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1118</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm1292">10.1038/nm1292</ext-link></comment>
<pub-id pub-id-type="pmid">16186818</pub-id></mixed-citation></ref><ref id="pone.0178669.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>McHeyzer-Williams</surname><given-names>M</given-names></name>, <name><surname>Okitsu</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>N</given-names></name>, <name><surname>McHeyzer-Williams</surname><given-names>L</given-names></name>. <article-title>Molecular programming of B cell memory</article-title>. <source>Nat Rev Immunol</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>24</fpage>&#x02013;<lpage>34</lpage>. PubMed Central PMCID: PMCPMC3947622. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri3128">10.1038/nri3128</ext-link></comment>
<pub-id pub-id-type="pmid">22158414</pub-id></mixed-citation></ref><ref id="pone.0178669.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Dogan</surname><given-names>I</given-names></name>, <name><surname>Bertocci</surname><given-names>B</given-names></name>, <name><surname>Vilmont</surname><given-names>V</given-names></name>, <name><surname>Delbos</surname><given-names>F</given-names></name>, <name><surname>Megret</surname><given-names>J</given-names></name>, <name><surname>Storck</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Multiple layers of B cell memory with different effector functions</article-title>. <source>Nat Immunol</source>. <year>2009</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1292</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.1814">10.1038/ni.1814</ext-link></comment>
<pub-id pub-id-type="pmid">19855380</pub-id></mixed-citation></ref><ref id="pone.0178669.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Manz</surname><given-names>RA</given-names></name>, <name><surname>Thiel</surname><given-names>A</given-names></name>, <name><surname>Radbruch</surname><given-names>A</given-names></name>. <article-title>Lifetime of plasma cells in the bone marrow</article-title>. <source>Nature</source>. <year>1997</year>;<volume>388</volume>(<issue>6638</issue>):<fpage>133</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/40540">10.1038/40540</ext-link></comment>
<pub-id pub-id-type="pmid">9217150</pub-id></mixed-citation></ref><ref id="pone.0178669.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Kantele</surname><given-names>A</given-names></name>, <name><surname>Pakkanen</surname><given-names>SH</given-names></name>, <name><surname>Karttunen</surname><given-names>R</given-names></name>, <name><surname>Kantele</surname><given-names>JM</given-names></name>. <article-title>Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines&#x02014;a randomized trial</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e60583</fpage> PubMed Central PMCID: PMCPMC3620468. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0060583">10.1371/journal.pone.0060583</ext-link></comment>
<pub-id pub-id-type="pmid">23593253</pub-id></mixed-citation></ref><ref id="pone.0178669.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Blanco</surname><given-names>F</given-names></name>, <name><surname>Isibasi</surname><given-names>A</given-names></name>, <name><surname>Raul</surname><given-names>GC</given-names></name>, <name><surname>Ortiz</surname><given-names>V</given-names></name>, <name><surname>Paniagua</surname><given-names>J</given-names></name>, <name><surname>Arreguin</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Human cell mediated immunity to porins from Salmonella typhi</article-title>. <source>Scand J Infect Dis</source>. <year>1993</year>;<volume>25</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="pmid">8384733</pub-id></mixed-citation></ref><ref id="pone.0178669.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Gil-Cruz</surname><given-names>C</given-names></name>, <name><surname>Bobat</surname><given-names>S</given-names></name>, <name><surname>Marshall</surname><given-names>JL</given-names></name>, <name><surname>Kingsley</surname><given-names>RA</given-names></name>, <name><surname>Ross</surname><given-names>EA</given-names></name>, <name><surname>Henderson</surname><given-names>IR</given-names></name>, <etal>et al</etal>
<article-title>The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>24</issue>):<fpage>9803</fpage>&#x02013;<lpage>8</lpage>. PubMed Central PMCID: PMCPMC2701014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0812431106">10.1073/pnas.0812431106</ext-link></comment>
<pub-id pub-id-type="pmid">19487686</pub-id></mixed-citation></ref><ref id="pone.0178669.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Nikaido</surname><given-names>H</given-names></name>. <article-title>Molecular basis of bacterial outer membrane permeability revisited</article-title>. <source>Microbiol Mol Biol Rev</source>. <year>2003</year>;<volume>67</volume>(<issue>4</issue>):<fpage>593</fpage>&#x02013;<lpage>656</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/MMBR.67.4.593-656.2003">10.1128/MMBR.67.4.593-656.2003</ext-link></comment>
<pub-id pub-id-type="pmid">14665678</pub-id></mixed-citation></ref><ref id="pone.0178669.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wahid</surname><given-names>R</given-names></name>, <name><surname>Simon</surname><given-names>R</given-names></name>, <name><surname>Zafar</surname><given-names>SJ</given-names></name>, <name><surname>Levine</surname><given-names>MM</given-names></name>, <name><surname>Sztein</surname><given-names>MB</given-names></name>. <article-title>Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans</article-title>. <source>Clin Vaccine Immunol</source>. <year>2012</year>;<volume>19</volume>(<issue>6</issue>):<fpage>825</fpage>&#x02013;<lpage>34</lpage>. PubMed Central PMCID: PMCPMC3370435. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00058-12">10.1128/CVI.00058-12</ext-link></comment>
<pub-id pub-id-type="pmid">22492745</pub-id></mixed-citation></ref></ref-list></back></article>